ZA983602B - Use of tetrahydropyridine derivatives for the preparation of drugs for the treatment of diseases which cause demyelination - Google Patents

Use of tetrahydropyridine derivatives for the preparation of drugs for the treatment of diseases which cause demyelination

Info

Publication number
ZA983602B
ZA983602B ZA983602A ZA983602A ZA983602B ZA 983602 B ZA983602 B ZA 983602B ZA 983602 A ZA983602 A ZA 983602A ZA 983602 A ZA983602 A ZA 983602A ZA 983602 B ZA983602 B ZA 983602B
Authority
ZA
South Africa
Prior art keywords
drugs
diseases
preparation
treatment
tetrahydropyridine derivatives
Prior art date
Application number
ZA983602A
Other languages
English (en)
Inventor
Bernard Bourrie
Pierre Casellas
Jean-Pierre Maffrand
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ZA983602B publication Critical patent/ZA983602B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA983602A 1997-04-29 1998-04-29 Use of tetrahydropyridine derivatives for the preparation of drugs for the treatment of diseases which cause demyelination ZA983602B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9705275A FR2762514B1 (fr) 1997-04-29 1997-04-29 Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation

Publications (1)

Publication Number Publication Date
ZA983602B true ZA983602B (en) 1998-11-02

Family

ID=9506415

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA983602A ZA983602B (en) 1997-04-29 1998-04-29 Use of tetrahydropyridine derivatives for the preparation of drugs for the treatment of diseases which cause demyelination

Country Status (18)

Country Link
US (1) US6344464B1 (de)
EP (1) EP0979079B1 (de)
JP (1) JP3956059B2 (de)
AR (1) AR012504A1 (de)
AT (1) ATE269077T1 (de)
AU (1) AU7436498A (de)
BR (1) BR9810234A (de)
CA (1) CA2288241C (de)
DE (1) DE69824576T2 (de)
DK (1) DK0979079T3 (de)
ES (1) ES2222593T3 (de)
FR (1) FR2762514B1 (de)
NO (1) NO325163B1 (de)
PT (1) PT979079E (de)
SI (1) SI0979079T1 (de)
UY (1) UY24973A1 (de)
WO (1) WO1998048802A1 (de)
ZA (1) ZA983602B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763847B1 (fr) * 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
EP1383762B1 (de) * 2001-04-20 2007-06-20 Sanofi-Aventis Tetrahydropyridyl-alkyl-heterozykle, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten
FR2823748B1 (fr) * 2001-04-20 2004-02-20 Sanofi Synthelabo Tetrahydropyridyl-alkyl-benzodiazines, procede pour leur preparation et compositions pharmaceutiques les contenant
AU2002316384A1 (en) * 2001-06-26 2003-03-03 Photomed Technologies, Inc. Multiple wavelength illuminator
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
FR2831166B1 (fr) * 2001-10-18 2004-02-27 Sanofi Synthelabo Aralkyl-tetrahydro-pyridines, leur preparation et compositions pharmaceutiques les contenant
MXPA05002514A (es) 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
ATE537164T1 (de) 2004-12-21 2011-12-15 Merck Serono Sa Zyklische sulfonylaminoderivate und deren verwendung als mmp-hemmer
ATE516279T1 (de) 2005-01-31 2011-07-15 Merck Serono Sa N-hydroxyamidderivate und ihre verwendung
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
EA200800342A1 (ru) * 2005-07-15 2008-08-29 Лаборатуар Сероно Са ИНГИБИТОРЫ Glepp-1 ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ И/ИЛИ ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
EP1933860A2 (de) 2005-09-01 2008-06-25 Ares Trading S.A. Behandlung von optikusneuritis
CN103351390A (zh) * 2007-11-21 2013-10-16 解码遗传Ehf公司 用于治疗肺部和心血管病症的联芳基pde4 抑制剂
KR101707597B1 (ko) * 2010-12-07 2017-02-17 한국전자통신연구원 홀 센서리스 ｂｌｄｃ 모터용 전원 공급 모듈
EP3836954B1 (de) 2018-08-13 2025-05-07 Iltoo Pharma Kombination von interleukin-2 mit einem interleukin-1-inhibitor, konjugate und therapeutische verwendungen davon
DK4452267T3 (da) 2021-12-23 2025-05-26 Cilcare Dev 4-phenyl-tetrahydropyridinderivater til behandling af hørelidelser
US20250283174A1 (en) 2022-05-16 2025-09-11 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2662355B1 (fr) 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
HU211019B (en) * 1991-12-02 1995-09-28 Richter Gedeon Vegyeszet Process for producing new 1,2,3,6-tetrahydropyridine and piperidine derivatives substituted with n-(hydroxylalkyl) group and compositions comprising such compounds
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2740343B1 (fr) 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique

Also Published As

Publication number Publication date
NO995245L (no) 1999-12-27
CA2288241C (en) 2006-10-03
FR2762514A1 (fr) 1998-10-30
BR9810234A (pt) 2000-09-19
NO325163B1 (no) 2008-02-11
UY24973A1 (es) 1998-07-16
ES2222593T3 (es) 2005-02-01
JP3956059B2 (ja) 2007-08-08
NO995245D0 (no) 1999-10-27
PT979079E (pt) 2004-10-29
ATE269077T1 (de) 2004-07-15
DE69824576D1 (de) 2004-07-22
DE69824576T2 (de) 2005-06-30
EP0979079A1 (de) 2000-02-16
SI0979079T1 (en) 2004-10-31
AU7436498A (en) 1998-11-24
CA2288241A1 (en) 1998-11-05
AR012504A1 (es) 2000-10-18
FR2762514B1 (fr) 1999-10-22
WO1998048802A1 (fr) 1998-11-05
DK0979079T3 (da) 2004-10-25
EP0979079B1 (de) 2004-06-16
US6344464B1 (en) 2002-02-05
JP2002501498A (ja) 2002-01-15

Similar Documents

Publication Publication Date Title
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
IL125735A0 (en) Pharmaceutical compositions for the treatment of glaucoma
IL127714A0 (en) Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic depressive bipolar disorders
AU2039800A (en) 5-membered heterocycles for the treatment of human diseases involving modulatorsof selectins
AU4048295A (en) Peptide medicaments for the treatment of disease
SI0979079T1 (en) Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination
GB2311940B (en) Pharmaceutical compositions for the treatment of rhinitis
HUP9900886A3 (en) Use of bisphosphonates preventing bone loss associated with immunosuppressive therapy for the preparation of pharmaceutical compositions
HUP0104963A3 (en) Compositions for the treatment of skin diseases
HUP9904027A3 (en) Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
AU3684395A (en) Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
AU2739497A (en) Use of vitamin d analogs for the treatment of arthritic disease
IL121096A0 (en) Pharmaceutical compositions for the treatment of liver disease
IL120005A0 (en) Pharmaceutical compositions for the treatment of the eye
HUP0003159A3 (en) The use of n-monosubstituted-3-oxo-4-aza-5alpha-androst-1-en-17betha-carboxamides for the preparation of pharmaceutical compositions
IL121647A0 (en) Pharmaceutical compositions for the treatment of ocular inflammations comprising dexamethasone palmitate
IL109235A0 (en) Pharmaceutical compositions containing ureido derivatives for the treatment of lentivirus-induced diseases
HUP0004647A3 (en) Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye
HUP0000569A3 (en) Use of equilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states
FI950010L (fi) Bradykiniiniantagonistien käyttö lääkeaineiden valmistamiseksi virussairauksien hoitamiseksi
PL350327A1 (en) Compositions for the treatment of skin diseases
HUP9801985A3 (en) Use of cystine derivatives for the preparation of pharmaceutical compositions useful for the treatment of restenosis
ZA945651B (en) Use of benzenesulphonzlindole derivatives for the preparation of medicines
KR100248098B1 (en) Pharmaceutical composition for the treatment of dementia